BioNTech Names Sobi CEO Guido Oelkers to Replace Co-Founder Ugur Sahin
The German biotech pioneer appoints pharmaceutical veteran with track record of scaling organizations as it transitions toward becoming a multi-product commercial company.
Leadership Transition at Mainz Headquarters
BioNTech SE announced a landmark leadership transition Monday, with its Supervisory Board appointing Guido Oelkers, Ph.D., as Chief Executive Officer to succeed co-founder Prof. Ugur Sahin, M.D. Oelkers will assume the role by February 1, 2027, at the latest, according to a 6-K filing with the Securities and Exchange Commission (6-K filing, 2026-08-03).
The appointment marks a pivotal moment for the German biotechnology company, which gained global prominence through its COVID-19 vaccine but is now focused on transforming into a diversified biopharmaceutical enterprise centered on oncology.
Proven Track Record in Pharma
Oelkers joins BioNTech from Swedish Orphan Biovitrum AB (Sobi), where he has served as CEO since 2017. During his nine-year tenure, he "more than quadrupled the company's revenues" between financial years 2017 and 2026 while "significantly increased Sobi's profitability and strengthened its late-stage pipeline" (6-K filing, 2026-08-03).
The incoming CEO brings over 30 years of pharmaceutical and biotechnology experience, having previously led BSN Medical, Gambro AB, and Invida Holdings, along with executive roles at Nycomed, Aventis Pharma China, and Hoechst AG. He holds a Ph.D. in Business Management from Adelaide University and will be based at BioNTech's Mainz, Germany headquarters.
"Guido Oelkers is an experienced executive in the pharmaceutical industry," said Helmut Jeggle, Chairman of BioNTech's Supervisory Board. "His expertise in scaling innovation-driven organizations in a focused and capital-efficient manner, coupled with his deep knowledge in relevant markets, will position the Company well to deliver on its key objectives to become a multi-product company" (6-K filing, 2026-08-03).
Strategic Focus on Oncology Pipeline
Oelkers highlighted BioNTech's oncology assets as a key attraction, stating: "BioNTech stands out through its scientific foundation and particularly its strong late-stage oncology pipeline." He expressed his commitment to "prioritizing its evolution into a global biopharmaceutical company with multiple approved products by 2030" (6-K filing, 2026-08-03).
The company's late-stage oncology pipeline includes immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies, supported by partnerships with Bristol Myers Squibb, Genentech (Roche Group), Genmab, and Pfizer, among others.
Founders' Next Chapter
Prof. Sahin, who co-founded BioNTech with his wife Prof. Özlem Türeci, M.D., praised the selection: "I have come to know Guido Oelkers as a leader who combines a deep understanding of the pharmaceutical industry and strong strategic acumen with genuine respect for the culture and people of our organization." Sahin committed to "actively supporting his onboarding" to ensure a smooth transition (6-K filing, 2026-08-03).
As previously announced, Prof. Türeci will transition from her role as Chief Medical Officer to lead a new independent company alongside her husband. The search for her successor "is ongoing and focuses on identifying a leader with exceptional medical and scientific expertise" and experience in late-stage clinical development (6-K filing, 2026-08-03).
BioNTech is scheduled to report second-quarter 2026 results on August 4, according to MarginX data. The $23 billion market-cap company closed at $92.25 in its most recent trading session.
This article was generated by MarginX from the 6-K filing on 2026-08-03. It is not investment advice.